Columnist Caroline Gainer weighs in on how changes with her doctors have affected her ability to coordinate care for her COPD ...

Digital inhalers that allow remote patient monitoring may predict impending exacerbations, or episodes when symptoms of COPD ...

Yupelri (revefenacin) is an approved once-daily maintenance therapy developed by Theravance Biopharma and Mylan (now part of Viatris) for chronic obstructive pulmonary disease (COPD). Its U.S.

COPD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for ...

COPD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for ...

Recently, I received a phone call from a longtime patient named Mrs. M., inquiring about a new portable oxygen concentrator (POC) she was planning to buy with her own money. She was told by one of the ...

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer ...

Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder that causes several symptoms which make breathing difficult. These include persistent cough with mucus, wheezing, and shortness ...

While the risk of COPD was highest among traditional cigarette smokers and dual users, e-cigarette users also had a significantly increased risk of COPD over people who’d never used e-cigarettes or ...

Fatigue is one of the most common symptoms of COPD, so it's important to understand what causes it, columnist Caroline Gainer says.

Budesonide for inhalation (brand name, Pulmicort; AstraZeneca) is a corticosteroid used to prevent breathing difficulties, chest tightness, wheezing, and coughing caused by respiratory disorders, such ...

Abrysvo was already cleared in the U.S. for adults older than 60 and pregnant people at 32-36 weeks of gestation to protect infants from birth to age 6 months. With the new authorization, Abrysvo ...